INmune Bio (NASDAQ:INMB) Stock Rating Lowered by Wall Street Zen

INmune Bio (NASDAQ:INMB) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

INmune Bio Trading Up 6.3%

NASDAQ:INMB opened at $1.51 on Friday. The stock has a market capitalization of $40.14 million, a PE ratio of -0.71 and a beta of 0.72. INmune Bio has a 1-year low of $1.38 and a 1-year high of $11.64. The firm has a fifty day simple moving average of $1.70 and a 200 day simple moving average of $1.92.

Institutional Trading of INmune Bio

A number of hedge funds have recently made changes to their positions in INMB. Vanguard Group Inc. lifted its holdings in INmune Bio by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 876,292 shares of the company’s stock valued at $1,814,000 after purchasing an additional 28,541 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of INmune Bio by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock worth $901,000 after buying an additional 25,069 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of INmune Bio by 240.9% during the 2nd quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock worth $291,000 after buying an additional 88,928 shares during the period. Westside Investment Management Inc. grew its stake in INmune Bio by 384.0% in the 3rd quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock valued at $214,000 after buying an additional 82,075 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in INmune Bio by 1,042.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock valued at $169,000 after acquiring an additional 66,700 shares during the period. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.